Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aldeyra Therapeu (ALDX)

Aldeyra Therapeu (ALDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 293,595
  • Shares Outstanding, K 60,163
  • Annual Sales, $ 0 K
  • Annual Income, $ -55,850 K
  • EBIT $ -45 M
  • EBITDA $ -47 M
  • 60-Month Beta 0.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.92

Options Overview Details

View History
  • Implied Volatility 331.17% (+56.69%)
  • Historical Volatility 55.95%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 331.17% on 12/05/25
  • IV Low 56.89% on 08/08/25
  • Expected Move (DTE 14) 2.23 (47.38%)
  • Put/Call Vol Ratio 0.88
  • Today's Volume 1,523
  • Volume Avg (30-Day) 1,012
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 40,800
  • Open Int (30-Day) 31,348
  • Expected Range 2.47 to 6.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.20
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +37.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.53 +3.87%
on 11/07/25
5.68 -17.25%
on 11/28/25
-0.23 (-4.67%)
since 11/05/25
3-Month
4.53 +3.87%
on 11/07/25
5.88 -20.00%
on 09/10/25
-0.86 (-15.47%)
since 09/05/25
52-Week
1.14 +312.28%
on 04/03/25
7.20 -34.72%
on 03/12/25
-0.25 (-5.05%)
since 12/05/24

Most Recent Stories

More News
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at a...

ALDX : 4.70 (-3.69%)
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced...

ALDX : 4.70 (-3.69%)
Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that the...

ALDX : 4.70 (-3.69%)
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

Relative to Baseline, Signal-Finding Molecule ADX‑629 Demonstrated Statistically Significant Improvement in Liver Function in Patients with Alcohol-Associated Hepatitis RASP Modulator...

ALDX : 4.70 (-3.69%)
Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases,...

ALDX : 4.70 (-3.69%)
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection, USP)...

ALDX : 4.70 (-3.69%)
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection,...

ALDX : 4.70 (-3.69%)
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases,...

ALDX : 4.70 (-3.69%)
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection) for...

ALDX : 4.70 (-3.69%)
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics

For Immediate ReleaseChicago, IL – July 17, 2025 – Today, Zacks Equity Research discusses Catalyst Pharmaceuticals CPRX, Zevra Therapeutics ZVRA, Theravance Biopharma TBPH, Aldeyra Therapeutics ALDX...

TBPH : 18.55 (-0.80%)
ALDX : 4.70 (-3.69%)
ZVRA : 8.71 (+0.58%)
LRMR : 3.70 (+0.54%)
CPRX : 23.53 (+1.95%)

Business Summary

Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 5.21
2nd Resistance Point 5.09
1st Resistance Point 4.90
Last Price 4.70
1st Support Level 4.59
2nd Support Level 4.47
3rd Support Level 4.28

See More

52-Week High 7.20
Fibonacci 61.8% 4.89
Last Price 4.70
Fibonacci 50% 4.17
Fibonacci 38.2% 3.45
52-Week Low 1.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar